No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.

Sarah J SchepKathelijn FischerMarianne BoesRoger E G Schutgens

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)

Switching to a different FVIII product was not associated with inhibitor development, nor with differences in the immune profile. Switching to rFVIII-Fc lead to lower ABR.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
optical coherence tomography
patient reported outcomes
data analysis